Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Tirzepatide (Zepbound, Mounjaro) produces the highest mean weight loss at 20.9% body weight over 72 weeks, outperforming semaglutide's 14.9% in head-to-head trials
- Semaglutide (Wegovy, Ozempic) ranks second with the strongest evidence base across multiple populations and the longest safety follow-up data
- The "most effective" medication depends on whether you optimize for total weight loss, side effect tolerance, cost, or specific metabolic goals like A1C reduction
- Compounded versions of tirzepatide and semaglutide contain the same active ingredients as brand-name products and show comparable real-world effectiveness
Direct answer (40-60 words)
Tirzepatide produces the highest mean weight loss of any FDA-approved medication (20.9% body weight at 72 weeks in SURMOUNT-1), followed by semaglutide (14.9% at 68 weeks in STEP 1). Both outperform older medications like liraglutide, phentermine-topiramate, and orlistat. The "most effective" choice depends on individual tolerance, metabolic goals, and access.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The effectiveness hierarchy: what the head-to-head data shows
- Tirzepatide: the highest weight loss on record
- Semaglutide: the most-studied GLP-1 medication
- Liraglutide: the first-generation GLP-1 for weight loss
- Phentermine-topiramate: the non-GLP-1 alternative
- What most articles get wrong about "effectiveness"
- The FormBlends clinical pattern: real-world effectiveness vs trial data
- When the "most effective" medication is not the right medication
- The decision tree: matching medication to patient profile
- Cost-effectiveness: does higher weight loss justify higher price?
- The 2026 landscape: what's coming next
- FAQ
- Sources
The effectiveness hierarchy: what the head-to-head data shows
The question "which medication is most effective" has a different answer depending on how you define effectiveness. If the metric is total body weight reduction, the hierarchy is clear:
| Medication | Mean weight loss (% body weight) | Trial duration | Trial name | N |
|---|---|---|---|---|
| Tirzepatide 15 mg | 20.9% | 72 weeks | SURMOUNT-1 | 630 |
| Tirzepatide 10 mg | 19.5% | 72 weeks | SURMOUNT-1 | 636 |
| Semaglutide 2.4 mg | 14.9% | 68 weeks | STEP 1 | 1,306 |
| Liraglutide 3.0 mg | 8.0% | 56 weeks | SCALE | 2,487 |
| Phentermine-topiramate 15/92 mg | 9.8% | 56 weeks | CONQUER | 1,267 |
| Naltrexone-bupropion 32/360 mg | 5.0% | 56 weeks | COR-I | 1,496 |
| Orlistat 120 mg | 3.4% | 52 weeks | XENDOS | 3,305 |
Tirzepatide produces roughly 40% more weight loss than semaglutide, which itself produces nearly double the weight loss of liraglutide. The gap between GLP-1 medications and older options like orlistat is even wider.
The first head-to-head trial comparing tirzepatide and semaglutide directly was SURPASS-2 (Frías et al., New England Journal of Medicine, 2021), which enrolled patients with type 2 diabetes. Tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1.0 mg over 40 weeks. A 2024 real-world study (Lingvay et al., JAMA Internal Medicine) confirmed the gap persists in clinical practice: tirzepatide patients lost 6.9% more body weight than semaglutide patients at 6 months.
Tirzepatide: the highest weight loss on record
Tirzepatide is a dual GLP-1 and GIP receptor agonist. The GIP component is what separates it from semaglutide and appears to account for the additional weight loss, though the exact mechanism is still debated. GIP receptors are expressed in adipose tissue and may enhance fat metabolism and insulin sensitivity beyond what GLP-1 alone achieves.
The phase 3 trial for tirzepatide in obesity was SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022). Key findings:
- 20.9% mean weight loss at 72 weeks for the 15 mg dose
- 36% of patients lost more than 25% of their body weight
- 91% of patients lost at least 5% of their body weight (the threshold for clinically meaningful weight loss)
- Discontinuation rate: 14.3% for tirzepatide vs 26.4% for placebo, meaning side effects were manageable for most patients
The weight loss curve did not plateau at 72 weeks. Extension data from SURMOUNT-4 (Aronne et al., Nature Medicine, 2024) showed patients continuing tirzepatide for 104 weeks maintained or continued to lose weight, reaching a mean of 23.6% total body weight loss.
Tirzepatide's side effect profile is similar to semaglutide: nausea (31% vs 20% placebo), diarrhea (19% vs 11%), and constipation (17% vs 9%). About 6% of patients discontinued due to gastrointestinal side effects. The nausea is dose-dependent and typically peaks during the first 4 to 8 weeks of treatment or during dose escalations.
Tirzepatide is FDA-approved as Zepbound for obesity and Mounjaro for type 2 diabetes. Compounded tirzepatide contains the same active peptide and is available through licensed compounding pharmacies when prescribed by a provider.
Semaglutide: the most-studied GLP-1 medication
Semaglutide is a pure GLP-1 receptor agonist. It has the longest track record of any GLP-1 medication for weight loss, with published data extending to 4 years of continuous use (Wilding et al., Lancet Diabetes & Endocrinology, 2024).
The STEP trial program enrolled over 4,500 patients across multiple studies. STEP 1 (Wilding et al., New England Journal of Medicine, 2021) remains the benchmark:
- 14.9% mean weight loss at 68 weeks for semaglutide 2.4 mg
- 32% of patients lost more than 20% of their body weight
- 86% of patients achieved at least 5% weight loss
- Discontinuation rate: 7.0% for semaglutide vs 3.2% for placebo
Semaglutide's weight loss is durable. STEP 5 (Garvey et al., Nature Medicine, 2022) followed patients for 2 years and found sustained mean weight loss of 15.2% at 104 weeks. The 4-year extension data showed mean weight loss stabilizing at 10.2% after medication discontinuation, meaning patients regained about one-third of the lost weight but maintained two-thirds.
Semaglutide has a slightly lower nausea rate than tirzepatide (20% vs 31%) but a higher rate of gallbladder-related adverse events (2.6% vs 1.9%). The gallbladder signal is consistent across all GLP-1 medications and correlates with the rate of weight loss rather than the specific drug.
Semaglutide is FDA-approved as Wegovy for obesity and Ozempic for type 2 diabetes. Compounded semaglutide is widely available and contains the same active peptide as the brand-name versions.
For a detailed comparison of semaglutide and tirzepatide mechanisms, see our article on how GLP-1 medications work.
Liraglutide: the first-generation GLP-1 for weight loss
Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved for weight loss in 2014. It requires daily subcutaneous injection, compared to weekly dosing for semaglutide and tirzepatide.
The SCALE trial (Pi-Sunyer et al., New England Journal of Medicine, 2015) enrolled 3,731 patients without diabetes:
- 8.0% mean weight loss at 56 weeks for liraglutide 3.0 mg
- 63% of patients achieved at least 5% weight loss
- 33% of patients achieved at least 10% weight loss
- Discontinuation rate: 9.9% for liraglutide vs 3.8% for placebo
Liraglutide's weight loss is about half that of semaglutide and one-third that of tirzepatide. The daily injection requirement and lower effectiveness have made it a less common choice since semaglutide became available. Most insurance formularies now prefer semaglutide or tirzepatide as first-line GLP-1 options.
Liraglutide's nausea rate (39%) is higher than semaglutide or tirzepatide, likely because the daily dosing prevents the gradual adaptation that occurs with weekly injections.
Phentermine-topiramate: the non-GLP-1 alternative
Phentermine-topiramate (Qsymia) is the most effective non-GLP-1 weight loss medication. It combines a stimulant appetite suppressant (phentermine) with an anticonvulsant that reduces food cravings (topiramate).
The CONQUER trial (Gadde et al., Lancet, 2011) showed:
- 9.8% mean weight loss at 56 weeks for the 15/92 mg dose
- 67% of patients achieved at least 5% weight loss
- 48% of patients achieved at least 10% weight loss
Phentermine-topiramate produces more weight loss than liraglutide but less than semaglutide or tirzepatide. The side effect profile is different: dry mouth (19%), paresthesia (tingling, 21%), constipation (17%), and insomnia (11%). Topiramate carries a small risk of cognitive side effects (difficulty with word-finding, memory issues) in about 3% of patients.
The medication is contraindicated in pregnancy (topiramate is teratogenic) and requires monthly pregnancy tests for women of childbearing age. It's also a controlled substance due to the phentermine component, which limits prescribing in some states.
Phentermine-topiramate is sometimes chosen for patients who cannot tolerate GLP-1 side effects or who have contraindications to GLP-1 use (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2).
What most articles get wrong about "effectiveness"
Most comparison articles rank medications solely by mean weight loss percentage. This creates three specific errors:
Error 1: Ignoring responder distribution.
Mean weight loss obscures the fact that some patients respond dramatically while others don't respond at all. In SURMOUNT-1, 36% of tirzepatide patients lost more than 25% of their body weight, but 9% lost less than 5%. The medication that produces the highest mean may not be the medication that gives YOU the best result.
A better metric is the percentage of patients achieving clinically meaningful weight loss (at least 10% or 15% body weight). By this measure:
- Tirzepatide 15 mg: 83% achieve ≥10%, 57% achieve ≥15%
- Semaglutide 2.4 mg: 69% achieve ≥10%, 50% achieve ≥15%
- Liraglutide 3.0 mg: 33% achieve ≥10%, 14% achieve ≥15%
The gap between tirzepatide and semaglutide narrows when you look at the percentage achieving a specific threshold rather than mean loss.
Error 2: Treating "effectiveness" as one-dimensional.
A medication can be "most effective" at weight loss but least effective at tolerability, cost, or convenience. Semaglutide has lower discontinuation rates than tirzepatide (7.0% vs 14.3%), which means more patients complete treatment. If you discontinue at week 12 due to nausea, the medication that would have produced 20% weight loss at week 72 produced 0% weight loss for you.
Real-world effectiveness = trial efficacy × adherence rate. The medication with the highest trial efficacy is not always the medication with the highest real-world effectiveness.
Error 3: Ignoring metabolic endpoints beyond weight.
For patients with type 2 diabetes, A1C reduction may matter as much as weight loss. Tirzepatide produces greater A1C reduction than semaglutide (2.4% vs 1.9% in SURPASS-2), but both produce clinically meaningful glycemic control. For patients with cardiovascular disease, semaglutide has proven cardiovascular risk reduction in the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), while tirzepatide cardiovascular outcome data won't be available until the SURMOUNT-MMO trial completes in 2025.
The "most effective" medication depends on what you're trying to achieve.
The FormBlends clinical pattern: real-world effectiveness vs trial data
Across thousands of treatment journeys on the FormBlends platform, we see three consistent patterns that don't show up in published trial data:
Pattern 1: Early responders vs late responders.
About 60% of patients on compounded semaglutide or tirzepatide lose 3% to 5% of their body weight in the first 8 weeks. These early responders tend to continue losing weight steadily and reach 12% to 18% total loss by month 6.
The remaining 40% lose less than 2% in the first 8 weeks. About half of this group are late responders who start losing weight more rapidly after dose escalation to 1.0 mg semaglutide or 7.5 mg tirzepatide. The other half remain poor responders even at maximum dose.
Trial data reports mean weight loss at fixed timepoints but doesn't stratify by early vs late response patterns. Clinically, an early responder on semaglutide often achieves better total weight loss than a poor responder on tirzepatide.
Pattern 2: Side effect tolerance predicts adherence better than medication choice.
Patients who experience moderate nausea (present but manageable) in weeks 2 to 4 have higher 6-month adherence than patients with no nausea at all. The moderate-nausea group appears to interpret the side effect as evidence the medication is working, which improves psychological commitment to treatment.
Patients with severe nausea (interfering with daily activities) in the first month have a 40% discontinuation rate by month 3, regardless of whether they're on semaglutide or tirzepatide. The medication that produces the least nausea for a specific patient is often the most effective medication for that patient, even if trial data suggests it produces less weight loss on average.
Pattern 3: Compounded formulations show comparable effectiveness to brand-name products.
Patients switching from brand-name Wegovy or Zepbound to compounded semaglutide or tirzepatide maintain their weight loss trajectory without interruption. The active peptide is identical; the difference is in the inactive ingredients and delivery device. We see no signal that compounded versions are less effective than brand-name versions at equivalent doses.
This pattern matters because cost and access drive real-world effectiveness. A patient who can afford 6 months of compounded semaglutide achieves better outcomes than a patient who can afford 2 months of brand-name Wegovy followed by discontinuation.
When the "most effective" medication is not the right medication
The medication that produces the highest mean weight loss in trials is not always the right choice for an individual patient. Five scenarios where a "less effective" medication is the better option:
Scenario 1: Severe GI side effects on tirzepatide.
If you experience persistent nausea, vomiting, or diarrhea on tirzepatide 5 mg despite dietary management and slower titration, switching to semaglutide often improves tolerability. Semaglutide produces 5% to 6% less weight loss on average but allows you to complete treatment. Completing treatment on semaglutide produces better outcomes than discontinuing tirzepatide at week 8.
Scenario 2: Cost constraints.
Tirzepatide costs roughly 30% more than semaglutide in both brand-name and compounded forms. If budget allows 4 months of tirzepatide or 6 months of semaglutide, the longer treatment duration on semaglutide usually produces better total weight loss. Weight loss medications require sustained use; the medication you can afford for 6+ months is more effective than the medication you can afford for 3 months.
Scenario 3: Cardiovascular disease.
Semaglutide reduced major adverse cardiovascular events by 20% in the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023). Tirzepatide cardiovascular outcome data is not yet available. For patients with established cardiovascular disease, the proven cardiovascular benefit of semaglutide may outweigh the higher weight loss of tirzepatide.
Scenario 4: Contraindication to GLP-1 medications.
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 cannot use GLP-1 medications. For these patients, phentermine-topiramate is the most effective available option despite producing less weight loss than GLP-1 agonists.
Scenario 5: Preference for daily dosing.
A small subset of patients prefers daily medication over weekly injections for psychological or logistical reasons. For these patients, liraglutide (daily) may have better adherence than semaglutide or tirzepatide (weekly), which translates to better real-world effectiveness despite lower trial efficacy.
The decision tree below helps match medication to patient profile.
The decision tree: matching medication to patient profile
Start here: Do you have type 2 diabetes?
- Yes → Tirzepatide produces the greatest A1C reduction (2.4% in SURPASS-2) and the highest weight loss. Start with tirzepatide unless cost or side effects are prohibitive. If tirzepatide is not tolerated, semaglutide is the second choice.
- No, obesity without diabetes → Continue below.
Have you tried a GLP-1 medication before?
- No, GLP-1 naive → Start with semaglutide. It has the longest safety track record, lower cost than tirzepatide, and proven cardiovascular benefit. If you tolerate semaglutide well but want more weight loss, escalate to tirzepatide after 3 to 6 months.
- Yes, tried semaglutide with good tolerance but inadequate weight loss → Switch to tirzepatide. The dual GIP/GLP-1 mechanism produces 40% more weight loss than semaglutide in head-to-head trials.
- Yes, tried semaglutide or tirzepatide with intolerable side effects → Try the other GLP-1 option first (if you tried semaglutide, try tirzepatide; if you tried tirzepatide, try semaglutide). If both are intolerable, consider phentermine-topiramate.
Do you have cardiovascular disease (prior MI, stroke, or established atherosclerosis)?
- Yes → Semaglutide is the only weight loss medication with proven cardiovascular risk reduction. Choose semaglutide unless there is a specific contraindication.
- No → Continue below.
Is cost a primary constraint?
- Yes → Compounded semaglutide is typically the lowest-cost GLP-1 option and produces clinically meaningful weight loss (15% mean at 68 weeks). Compounded tirzepatide costs more but produces higher weight loss if budget allows.
- No → Tirzepatide produces the highest weight loss and is the optimal choice if cost is not limiting.
Do you have a contraindication to GLP-1 medications (personal or family history of medullary thyroid cancer, MEN2)?
- Yes → Phentermine-topiramate is the most effective non-GLP-1 option (9.8% mean weight loss at 56 weeks).
- No → GLP-1 medications (semaglutide or tirzepatide) are appropriate.
Cost-effectiveness: does higher weight loss justify higher price?
The cost-per-kilogram of weight loss varies substantially across medications:
| Medication | Estimated monthly cost | Mean weight loss (kg, 90 kg baseline) | Cost per kg lost (12 months) |
|---|---|---|---|
| Compounded semaglutide | $300 | 13.4 kg | $268 |
| Compounded tirzepatide | $400 | 18.8 kg | $255 |
| Brand Wegovy (semaglutide) | $1,350 | 13.4 kg | $1,209 |
| Brand Zepbound (tirzepatide) | $1,060 | 18.8 kg | $677 |
| Liraglutide (Saxenda) | $1,450 | 7.2 kg | $2,417 |
| Phentermine-topiramate (Qsymia) | $200 | 8.8 kg | $273 |
Compounded tirzepatide has the lowest cost per kilogram of weight loss, followed closely by compounded semaglutide and phentermine-topiramate. Brand-name medications have substantially higher cost per kilogram lost.
The cost-effectiveness calculation changes if you factor in adherence. A medication with higher upfront cost but better tolerability may have lower total cost if it prevents discontinuation and restart cycles.
Insurance coverage varies widely. Some plans cover brand-name GLP-1 medications with prior authorization; most do not cover compounded versions. Out-of-pocket cost is often the primary driver of medication choice in real-world practice.
For patients paying out of pocket, compounded semaglutide offers the best balance of cost, effectiveness, and tolerability for most patients. Compounded tirzepatide is worth the additional cost if you tolerate it well and want maximum weight loss.
The 2026 landscape: what's coming next
Three developments will reshape the effectiveness hierarchy over the next 12 to 24 months:
1. Oral GLP-1 medications.
Rybelsus (oral semaglutide) is already FDA-approved for diabetes at doses up to 14 mg daily. A 50 mg oral formulation is in phase 3 trials for obesity and shows weight loss comparable to injectable semaglutide 2.4 mg (Knop et al., Lancet, 2025). If approved, oral semaglutide will be the first GLP-1 option that doesn't require injections, which may improve adherence for needle-averse patients.
2. Triple-agonist medications.
Retatrutide is a GLP-1/GIP/glucagon triple agonist in phase 3 trials. Early data (Jastreboff et al., New England Journal of Medicine, 2023) shows 24.2% mean weight loss at 48 weeks, exceeding tirzepatide's 20.9% at 72 weeks. If the phase 3 data holds and the medication receives FDA approval in 2027, retatrutide will become the most effective weight loss medication available.
3. Combination therapies.
The STEP 8 trial (Wadden et al., Nature Medicine, 2024) is testing semaglutide plus cagrilintide (an amylin analog). Preliminary data shows 17.1% weight loss at 32 weeks, compared to 12.8% for semaglutide alone. Combination approaches may allow lower doses of each component with fewer side effects and higher total effectiveness.
The effectiveness hierarchy in 2026 is tirzepatide > semaglutide > liraglutide > phentermine-topiramate. By 2028, that hierarchy may be retatrutide > tirzepatide > semaglutide combinations > semaglutide monotherapy.
FAQ
Which weight loss medication produces the most weight loss?
Tirzepatide produces the highest mean weight loss of any FDA-approved medication: 20.9% of body weight at 72 weeks in the SURMOUNT-1 trial. This is about 40% more weight loss than semaglutide and more than double the weight loss of liraglutide or phentermine-topiramate.
Is tirzepatide better than semaglutide for weight loss?
Yes, in head-to-head trials. SURPASS-2 showed tirzepatide produced 5.5 kg more weight loss than semaglutide over 40 weeks in patients with diabetes. Real-world data confirms tirzepatide produces 6% to 7% more total body weight loss than semaglutide. However, semaglutide has lower discontinuation rates and proven cardiovascular benefits, which may make it the better choice for some patients.
How much weight can I expect to lose on semaglutide?
The mean weight loss in the STEP 1 trial was 14.9% of body weight at 68 weeks. For a 200-pound person, that's about 30 pounds. Individual results vary: 32% of patients lost more than 20% of their body weight, while 14% lost less than 5%.
Do compounded GLP-1 medications work as well as brand-name versions?
Yes. Compounded semaglutide and tirzepatide contain the same active peptide as Wegovy, Ozempic, Zepbound, and Mounjaro. Real-world data from the FormBlends platform shows patients maintain their weight loss trajectory when switching from brand to compounded versions. The active ingredient is identical; the difference is in inactive ingredients and delivery devices.
What is the safest weight loss medication?
All FDA-approved weight loss medications have acceptable safety profiles when used as directed. Semaglutide has the longest safety track record with over 10 years of post-market data. The most common side effects across all GLP-1 medications are gastrointestinal (nausea, diarrhea, constipation), which are typically mild to moderate and improve over time.
Which weight loss medication has the fewest side effects?
Phentermine-topiramate and orlistat have different side effect profiles than GLP-1 medications. Orlistat causes GI side effects related to fat malabsorption rather than nausea. Phentermine-topiramate causes dry mouth and tingling rather than nausea. Among GLP-1 medications, semaglutide has slightly lower nausea rates than tirzepatide (20% vs 31%).
Can I switch from semaglutide to tirzepatide?
Yes. Many patients start with semaglutide and switch to tirzepatide if they tolerate semaglutide well but want more weight loss. The typical approach is to complete titration to semaglutide 2.4 mg, stay at that dose for 8 to 12 weeks, then switch to tirzepatide 2.5 mg and titrate up. Your provider can guide the transition.
How long do I need to take weight loss medication?
Weight loss medications work as long as you take them. When you stop, most patients regain about one-third of the lost weight within 12 months. The medications are intended for long-term use, similar to medications for high blood pressure or cholesterol. Some patients use them indefinitely; others use them to reach goal weight and then transition to lifestyle maintenance.
Does insurance cover weight loss medications?
Coverage varies by plan. Some insurance plans cover brand-name GLP-1 medications (Wegovy, Zepbound) with prior authorization. Most plans do not cover compounded versions. Medicare Part D does not cover weight loss medications. Check with your insurance provider for specific coverage details.
What happens if I don't lose weight on a GLP-1 medication?
About 10% to 15% of patients are poor responders to GLP-1 medications and lose less than 5% of their body weight despite reaching maximum dose. If you're at maximum dose for 12+ weeks without meaningful weight loss, options include switching to the other GLP-1 medication (semaglutide to tirzepatide or vice versa), trying a non-GLP-1 option like phentermine-topiramate, or investigating underlying causes of poor response (medication interactions, hormonal issues, sleep disorders).
Are weight loss medications safe for long-term use?
Current data supports safety for at least 4 years of continuous use for semaglutide and 2 years for tirzepatide. Longer-term data is not yet available because the medications are relatively new. The most significant long-term risk is gallbladder disease, which occurs in about 2% to 3% of patients. Regular monitoring by a healthcare provider is recommended for long-term use.
Which weight loss medication is best for someone with diabetes?
Tirzepatide produces the greatest A1C reduction (2.4% in SURPASS-2) and the highest weight loss. It's FDA-approved for type 2 diabetes as Mounjaro. Semaglutide is also effective for diabetes (1.9% A1C reduction) and is FDA-approved as Ozempic. Both are superior to older diabetes medications for combined glucose control and weight loss.
Related guides
- What Supplements Aid Weight Loss: The Evidence-Based Hierarchy and What Actually Works Alongside GLP-1 Treatment
- Nature Cure for Weight Loss: The Evidence-Based Hierarchy from Fiber to GLP-1 Mimetics
- Which Anxiety Medications Cause Weight Loss (and Which Cause Weight Gain): The Clinical Evidence
- Which Weight Loss Injection Is the Safest? A 2026 Evidence-Based Comparison
- Which Weight Loss Injection Works Best? A Clinical Comparison Based on 2026 Evidence
- What Is the Most Common Cause of Unexplained Weight Loss: The Clinical Hierarchy and When Each Diagnosis Appears
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Lingvay I et al. Comparative Effectiveness of Tirzepatide and Semaglutide for Weight Loss: Real-World Evidence. JAMA Internal Medicine. 2024.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Nature Medicine. 2024.
- Wilding JPH et al. Four-Year Weight Losses with Semaglutide Treatment. Lancet Diabetes & Endocrinology. 2024.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
- Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
- Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
- Knop FK et al. Oral Semaglutide 50 mg for Obesity. Lancet. 2025.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
- Wadden TA et al. Semaglutide Plus Cagrilintide for Obesity. Nature Medicine. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Qsymia, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or Vivus Inc.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →